Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system (2020) Schmidt M, Degenhardt T, Fasching P, Lueftner D, Mueller V, Thomssen C, Schem C, et al. Conference contribution Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases (2020) Laakmann E, Witzel I, Neunhoeffer T, Weide R, Schmidt M, Park-Simon TW, Mobus V, et al. Conference contribution Use of a molecular Registry (PRAEGNANT) for Patient-Selection and Biomarker-Analysis for the SHERBOC Study (2020) Hübner H, Kurbacher C, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, et al. Conference contribution Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry - comparison of three different prognostic scores (2020) Riecke K, Mueller , Neunhoeffer T, Weide R, Schmidt M, Park-Simon TW, Mundhenke C, et al. Conference contribution Influence of the Family Anamnesis of Breast or Ovarian Cancer on the pathological Complete Remission and the Prognosis in Patients with Breast Cancer after neoadjuvant Chemotherapy (2020) Gaß P, Haberle L, Hein A, Jud S, Lux MP, Hack C, Emons J, et al. Conference contribution Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup (2020) Emons J, Fasching P, Wunderle M, Heindl F, Rieger J, Horn F, Pelzer G, et al. Conference contribution Mammographic Density and Prognosis in Patients with primary Breast Cancer - Loss of Risk with increasing Age (2020) Heindl F, Fasching P, Hein A, Hack C, Heusinger K, Gaß P, Schulz-Wendtland R, et al. Conference contribution Progression-free survival and overall survival in patients with advanced her2-positive breast cancer treated with trastuzumab emtansine (T-dm1) after previous treatment with pertuzumab (2020) Michel LL, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, Häberle L, et al. Journal article Influence of CDK4/6 inhibitors on the peripheral immune response in hormone receptor-positive breast cancer (2020) Peuker CA, Yaghobramzi S, Grunert C, Keilholz L, Hennig S, Schaper S, Brucker S, et al. Conference contribution Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system (2020) Schmidt M, Degenhardt T, Fasching P, Lüftner D, Müller V, Thomssen C, Schem C, et al. Journal article